---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-118839"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:20:25.347290+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Verrica Q1 2025: YCANTH revenue $3.4M; dispensed 10,102 units (+16.7% QoQ)

## Summary
- Net loss $9.7M ($0.10/share) vs. $20.3M ($0.44) in Q1 2024; non-GAAP net loss $7.8M.
- YCANTH revenue $3.4M from >10K applicator units dispensed, a company record and 16.7% sequential growth.
- Cash and equivalents $29.6M as of March 31, 2025.
- Appointed Noah Rosenberg as CMO (March) and Gavin Corcoran to Board (April).
- Completed end-of-Phase 2 meeting with FDA for VP-315 (basal cell carcinoma); global Phase 3 for common warts advancing with Torii.

## SEC filing metadata
- accession: 0001193125-25-118839
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312525118839/0001193125-25-118839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312525118839/d88474d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-118839
- JSON: https://secwatch.observer/filing/0001193125-25-118839.json
- Plain text: https://secwatch.observer/filing/0001193125-25-118839.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.